Cognito HOPE
A Randomized, Double-blind, Sham-controlled, Adaptive- Design Pivotal Study of Sensory Stimulation in
Subjects with Alzheimer’s Disease
Purpose
The purpose of this study is to measure changes in function and cognition after 52 weeks of daily therapy with gamma sensory stimulation in participants with mild/moderate AD.
Who can participate
To participate in this study, the participant must meet the criteria listed below.
- Age 50 – 90 years old, inclusive
- Dx of mild to moderate AD
- MMSE 15-28, inclusive (15-20, sponsor now looking for moderate ALZ participants)
- Study Partner required
- Stable pharmacological treatment >30 days
- Must consent to ApoE genotyping
- Adequate visual acuity
- Must pass site administered hearing test
- Documented proof of amyloid or p-tau, by historical or screening through PET, LP, or p-Tau blood work